Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

@inproceedings{Sim2015LongtermCI,
  title={Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study},
  author={Rafael Sim{\'o} and Bruno Guerci and Guntram Schernthaner and Baptist Gallwitz and Juan Rosas-Guzm{\`a}n and Francesco Dotta and Andreas Festa and Ming Zhou and Jacek Kiljański},
  booktitle={Cardiovascular diabetology},
  year={2015}
}
OBJECTIVE The risk of cardiovascular morbidity and mortality is significantly increased in patients with diabetes; thus, it is important to determine whether glucose-lowering therapy affects this risk over time. Changes in cardiovascular risk markers were examined in patients with type 2 diabetes treated with exenatide twice daily (a glucagon-like peptide-1 receptor agonist) or glimepiride (a sulfonylurea) added to metformin in the EURopean EXenAtide (EUREXA) study. RESEARCH DESIGN AND… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review

International journal of environmental research and public health • 2016
View 9 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes: differences and similarities

A Lund, FK Knop, T. Vilsboll
Eur J Intern Med • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…